欧洲经济共同体监管文件。指导说明。病毒去除和灭活程序的验证。专利药品委员会：生物技术/药学特设工作组和药品安全工作组。 - Suppr

Suppr

超能文献

EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.

出版信息

Biologicals. 1991 Jul;19(3):247-51.

PMID:1954007

Abstract

摘要

相似文献

EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.欧洲经济共同体监管文件。指导说明。病毒去除和灭活程序的验证。专利药品委员会：生物技术/药学特设工作组和药品安全工作组。

Biologicals. 1991 Jul;19(3):247-51.

Note for guidance. Guidelines for medicinal products derived from human blood and plasma. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.指导说明。人血和血浆衍生药品指南。专利药品委员会：生物技术/药学特设工作组和药品安全工作组。

Biologicals. 1992 Jun;20(2):159-64.

Note for guidance. Production and quality control of human monoclonal antibodies. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.指导说明。人源单克隆抗体的生产与质量控制。专利药品委员会：生物技术/药学特设工作组及药品安全工作组。

Biologicals. 1991 Apr;19(2):133-8.

Note for guidance. Guidelines for minimizing the risk of transmitting agents causing spongiform encephalopathy via medicinal products. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.指导说明。关于将导致海绵状脑病的病原体通过药品传播的风险降至最低的指南。专利药品委员会：生物技术/药学特设工作组和药品安全工作组。

Biologicals. 1992 Jun;20(2):155-8.

Virus validation procedures: practical aspects.病毒验证程序：实际操作方面

Blood Coagul Fibrinolysis. 1995 Jul;6 Suppl 2:S10-2.

Note for guidance. Production and quality control of cytokine products derived by biotechnological processes. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.指导说明。生物技术工艺生产的细胞因子产品的生产与质量控制。专利药品委员会：生物技术/药学特设工作组及药品安全工作组。

Biologicals. 1991 Apr;19(2):125-31.

European project concerning the guidelines on medicinal products derived from human blood and plasma.欧洲关于人血和血浆衍生药品指南的项目。

Dev Biol Stand. 1991;75:237-40.

European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.欧洲关于重组蛋白、单克隆抗体和血浆衍生药品病毒安全性的监管指南。

Dev Biol (Basel). 2004;118:3-10.

[Viral safety: European and French directives].[病毒安全性：欧洲及法国指令]

Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S55-61.

Use of bacteriophages as surrogates for mammalian viruses.使用噬菌体作为哺乳动物病毒的替代物。

Dev Biol (Basel). 2004;118:89-98.

引用本文的文献

Acceptability of continuous cell lines for the production of biologicals.用于生物制品生产的连续细胞系的可接受性。

Cytotechnology. 1995 Jan;18(1-2):15-20. doi: 10.1007/BF00744315.

Pathogen safety of plasma-derived products - Haemate P/Humate-P.血浆衍生产品的病原体安全性 - 海莫莱士/人凝血酶原复合物

Haemophilia. 2008 Nov;14 Suppl 5(Suppl 5):54-71. doi: 10.1111/j.1365-2516.2008.01852.x.

C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.遗传性血管性水肿的C1抑制剂浓缩物家庭治疗：一种可行、有效的治疗选择。

Clin Exp Immunol. 2007 Jan;147(1):11-7. doi: 10.1111/j.1365-2249.2006.03256.x.

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.用氨甲环酸和长波长紫外线进行光化学处理使血小板浓缩物中的病毒失活。

Transfusion. 2005 Apr;45(4):580-90. doi: 10.1111/j.0041-1132.2005.04316.x.

Evaluation of the new serum-free medium (MDSS2) for the production of different biologicals: use of various cell lines.新型无血清培养基（MDSS2）用于生产不同生物制品的评估：多种细胞系的应用。

Cytotechnology. 1994;14(1):47-59. doi: 10.1007/BF00772195.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验